This episode discusses the urgent need for more effective and tolerable therapies for patients with EGFR-mutated NSCLC who have exhausted targeted treatments, comparing the clinical benefits of a targeted ADC approach vs chemotherapy, with a focus on the TROPION-Lung01 study of Dato-DXd vs docetaxel for heavily pretreated advanced/metastatic NSCLC with actionable genomic alterations.
This episode highlights the significance of third-generation EGFR TKIs in delaying subsequent therapies for resectable, stage IB to IIIA EGFR-mutated NSCLC, explores the risks of postresection treatments for disease progression, and discusses treatment considerations for patients across different stages, focusing on the ADAURA trial outcomes for stage IB to IIIA NSCLC.
Although the NCCN guidelines recommend osimertinib as an adjuvant therapy option, what is your position on its use for completely resected stage IB to IIIA NSCLC with less common EGFR activating mutations, such as exon 20 insertion?
This episode reviews the key takeaways from the ADAURA trial, discusses strategies for protecting the CNS in EGFR-mutated NSCLC, and examines the impact ADAURA had on recurrence rates in patients with completely resected EGFR-mutated NSCLC who were previously treated with adjuvant chemotherapy.
This episode delves into expert perspectives on the safety and tolerability of combining osimertinib with chemotherapy in untreated, advanced EGFR-mutated NSCLC, resistance to third-generation EGFR TKIs, the superiority of concurrent versus sequential therapy from the FLAURA2 study, the role of ctDNA in managing additional EGFR mutations, and decision-making in utilizing FLAURA2 for treatment selection.
This episode explores expert insights on the clinical use of osimertinib in the frontline setting for EGFR-mutated NSCLC, the impact of combining osimertinib with platinum-based chemotherapy on progression-free survival (PFS), and the significance of extending PFS by nearly 9 months in patients with advanced NSCLC who are not candidates for curative treatment.
Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.
Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.
Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.
Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.
Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.
A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.
Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.
Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.
Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.
Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.
Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.
A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.
A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.
A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.
Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.
Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.
Hatim Husain, MD, discusses common misconceptions that still exist with regard to lung cancer.
Hatim Husain, MD, discusses the evolution of liquid biopsies in lung cancer.
Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.
Hatim Husain, MD, discusses the increased use of and challenges with utilizing liquid biopsies.
Hatim Husain, MD, discusses the utility of liquid biopsy versus tissue biopsy in non–small cell lung cancer.
Hatim Husain, MD, assistant professor of Medicine, Moores Cancer Center, University of California, San Diego, discusses plasma-based testing in lung cancer.
Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).
Hatim Husain, MD, assistant professor of Hematology-Oncology at The University of California San Diego Moores Cancer Center, discusses his study on monitoring the emergence of EGFR T790M ctDNA in urine from EGFR-mutated NSCLC.
